Nova Patents
IS2154B

Stabilized preparations for use in metered dose inhalers

Abstract

Stabilized dispersions are provided for the delivery of a bioactive agent to the respiratory tract of a patient. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a hydrofluoroalkane propellant. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as, by settling or flocculation. In particularly preferred embodiments, the stabilized dispersions may be administered to the lung of a patient using a metered dose inhaler.

IS2154B, drawing sheet 1
Sheet 1 of 5

Term

Term ended

Expired 24 March 2020, 6.5 years ago.

  1. Priority
  2. Filed
  3. Granted
  4. Expired
  5. Today

18 claims: 13 independent, 5 dependent

  1. 1
    Demands:Kröfur: 1. Óhvarfgjdm upplausn, hæf til notkunar í öndunarvegi, til notkunar ί niflunartadci, sem samanstendur af flúorefhaupplausn ί samfelldum fasa, sem sviflausn, sem i er úrval holdttra drsamsetninga sem innihalda a.m.k. eitt Ufvirkt efiii, og par sem áðumefiid sviflausn gegndreypir holóttu drsamsetningamar að verulegu leyti. A disintegrant solution suitable for use in the respiratory tract, for use in a continuous phase, comprising a fluorine-containing continuous phase, as suspension comprising a solidified composition containing at least one inactive substance, and a pair of suspensions impregnating the cavity drip compositions substantially degree.
  2. 2
    The dissolution of the pair as the volume of the suspension emitted by the hollow core molecules is less than 70% of the median volume of those marketed by maiden peirra. 2. Upplausnin ί 1. krdfii par sem rúmmál sviflausnarinnar sem holóttu drsamsetnmgumnar ryðja frá sér er minna en 70% af medal rúmmáli þeiira sem markaðist af mærum peirra væru þær gegnheilar.
  3. 3
    The solutions of the first and second claims of the surfactants contain a surfactant compound which is desirable to be validated from a hydrochloride comprising phosphatidipid, nonionic fat, nonionic bit copolymers, ionic surfactants, continuous fluoride surfactant compounds and mixtures of peirra . 3. Upplausnin i l.og 2. kröfii par sem gðtuðu drsamsetningamar innihalda yfirborðsvirkt efiiasamband, sem æskilegt er að valid sé úr hdpi sem samanstendur af fosfatlípíði, ójónudum fituvætum, ójónudum bita-samfjölliðum, jónuðum yfirbordsvirkum efiiasambdndum, lifrsnum flúrudum yfirborðdvirkum efhasamböndum og blöndum peirra.
  4. 4
    The resolution of a third-stranded surfactant compound is phosphite lipid, which is desirably valid from a hdpi consisting of dilauroylphosphatidylcholine, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, dsteroylphosphitidilcholine, behenoylphosphatidylcholine, arakidoylphosphididylcholine. and their prayerfulness. 4. Upplausnin í 3. krdfo par sem nefiit yfirborðsvirkt efiiasamband er fosfittlipíð, sem æskilegt er að valid sé úr hdpi sem samanstendur af dilauroylphosphatidylcholíni, dioleylphosphatidylcholini, dipalmítoýlfosfetídýlkólíni, dísteroýlfosfetídilkólÍni, behenoýlfos&tídýlkólíni, arakidoýlfosfetidýl-kóllni. og bidndum þeirra.
  5. 5
    The resolution of each of the four to four pairs as a nefed suspension and the named sustained microsphere measurements has a fractional less than 0.5. 5. Upplausnin i hverri sem er af krdfiiml til 4 par sem nefed sviflausn og nefndu holdttu örsatnsetaingamar hafe brotsstudul minni en 0,5.
  6. 6
    The resolution of each of the five to five pairs containing the dromings is a hollow glossy global dromination. 6. Upplausnin i hverri sem er af krdfiiml til 5 par sem holdttu drsamsetningamar eru holar gljúpar hnattlaga drsamsetningar.
  7. 7
    The solution of any one of claims 1 to 6, characterized in that a non-active substance is comprised of dyspeptic agents, bronchodilators, bronchospasm agents, pulmonary embolisms, analgesics, antibiotics, inhibitors of leukotrins and antagonists, anticholinergic agents, antihistamines, antidepressants, antidiabetic agents, narcotics, tuberculosis drugs, resuscitation inhibitors, cardiovascular agents, enzymes, steroids, genitals, fibroids, antipsychotics, proteins, peptides and pandas. 7. Upplausnin ί hverri sem er af kröfum 1 til 6 par sem nefiit Ufvirkt efiii er valid úr hdpi sem samanstendur af dnsemisdei&ndi lyfjum, berkjuvikkandi lyfjum berkjusamdrattar lyfjum yfirbordsvirkum efnum i lungum, verkjalyfjum, syklalyfjum, tálmum leukótríena eda mótlyfjum, andkólínvirk lyfjum, andhistamini, bdlgueydandi lyfjum, sxliseydandi lyfjum, deyfilyfjum, berklalyfjum, gerandaefiii til myndatdku, hjarta-/sda gerandaefiii, ensimum, sterum, erfðaefiii, veimfeijum, andptettiefiu, prdteinum, peptidum og bidndum peirra.
  8. 8
    The resolution 1 of each son is from 7 to 7 pairs holding the drip formulations on average between 0.5 and 5pm per cent. 8. Upplausnin 1 hverri son er af krdfiiml til 7 par sem holdttu drsamsetningamar eru ad meðaltali á milli 0,5 og 5pm ad pvennáli.
  9. 11
    Notkun 10. krdfii par sem áðumefiid óhvarfgjöm upplauai inniheldur, dfiiga dropalausn, drdropalausn eda drsamsetningar ί sviflausn. 11. Use of a 10-step pair of inhibitor-containing solutions contains a single drop solution, diluent solution or suspension.
  10. 12
    Notkun 10. eda 11. krdfu par sem áðurnefht lifrirka efiii a gefid í útæðahringrás sjúklingsins. 12. Use of 10th or 11th of a pair of hepatocellular medicinal products administered during the patient's circulatory cycle.
  11. 13
    Adferd til ad jafna dreyfingu í öndunarfærum med pvi ad minnka van der Waals addrittarkrafla sem samanstanda af eftirferandi skrefun:13. Respiratory Respiratory Respiratory Response by reducing the Van der Waals additive tract consisting of the following steps: a. ad hafii til stadar fjdlda af götudum drsamsetningum;a. by sea to towns, many of the towns of dromings;I J’ In J ' L Iu4 L Iu4 b. integrate / combine / mix the hollow microorganism and fluoride solution containing at least one fluoride wherein the resolution retransmits the porous compositions and wherein the resolution and microassembly are chosen to have a fraction of less than 0.5. b. samþætta/sameina/blanda holóttu örsamsetningunnar og flúorefiia upplausnina sem inniheldur a.m.k. eitt flúorefiii þar sem upplausnin gengdreypir gljúpu ðrsamsetningamar og þar sem upplausnin og örsamsehiingamar eru valin til að hafá brotstuðul minni en 0,5.
  12. 17
    Adferdin í hverri sem er af kröfiim 13 til 17 þar sem nefndar holóttu örsamsetningar eru holar gljúpar örsamsetningar. The method of any one of claims 13 to 17 wherein said hollow microorganisms are hollow glazing microorganisms.
  13. 18
    Adferdin i hveni sem er af kröfiim 13 til 17 þar sem ne&t lffvirkt efiii er valid úr hópi sem samanstendur af ónæmisdeyfendi lyfjum, berkjuvfkkandi lyfjum, yfirbordsvirkum e&urn í lungum, verkjastillandi lyfjum, fiikkalyfjum, tálmum leukótrína eða módyfjum, andhistamfni, bdlgueydandi lyfjum, æxliseyðandi lyfjum, andkólfnvirkum lyfjum, deyfilyfjum, berklalyfjum, gerandaefhi til myndatöku, hjarta-/sða gerandaefhi, ensimum, sterum, erfðaefhi, veiruferjum, andþættiefhi, próteinum, peptíðum og samsetningar af þessu. 18. The method of any of claims 13 to 17 wherein said active substance is valid from a group consisting of immunosuppressive agents, bronchodilators, pulmonary embolisms, analgesics, antimicrobials, leukotrins or antidiabetic agents, antihistamines, antihypertensive agents, anti-narcotic drugs, anticholinergic drugs, narcotics, tuberculosis, retardation agents, cardiovascular agents, enzymes, steroids, genes, viruses, antivirals, proteins, peptides and combinations thereof.
Independent claims13